Related Experiment Video

Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and

Abdul Mueez Alam Kayani1, Muhammad Faiq Umar1, Daniel Navarro-Martinez2

  • 1Department of Internal Medicine, AdventHealth Tampa, Tampa, FL, United States of America.

Vascular Diseases (Paris, France)
|February 28, 2026
PubMed

Insights

Obicetrapib significantly improves lipid profiles, lowering LDL-C and Lp(a) while increasing HDL-C in high-risk Atherosclerotic Cardiovascular Disease patients. This cholesteryl ester transfer protein inhibitor showed no increased short-term adverse events in a recent meta-analysis.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death, with many high-risk patients failing to reach target low-density lipoprotein cholesterol (LDL-C) levels despite therapy.
  • Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, modifies lipoprotein profiles by inhibiting cholesterol ester transfer.

Purpose of the Study:

  • To evaluate the efficacy and safety of obicetrapib as an add-on therapy for high-risk ASCVD patients.
  • To assess obicetrapib's impact on various lipid parameters and adverse events.

Main Methods:

  • A systematic literature search was conducted across online databases.
  • Outcomes included percentage changes in LDL-C, HDL-C, non-HDL-C, triglycerides, ApoB, and lipoprotein (a) [Lp(a)].
  • Risk ratios and mean differences with 95% confidence intervals were calculated for categorical and continuous outcomes, respectively.

Main Results:

  • Analysis of three studies involving 3088 patients revealed significant reductions in LDL-C (-31.75%), non-HDL-C (-29.35%), Lp(a) (-35.67%), and ApoB (-19.37%).
  • Obicetrapib markedly increased HDL-C (+125.94%) with no significant change in total cholesterol or triglycerides.
  • No increased risk of adverse events, discontinuation, acute kidney injury, liver enzyme elevation, creatine kinase elevation, or hypertension was observed.

Conclusions:

  • Obicetrapib substantially improved lipid profiles in high-risk ASCVD patients receiving maximally tolerated lipid-lowering therapy.
  • The drug demonstrated a favorable short-term safety profile.
  • Long-term randomized studies are necessary to confirm sustained efficacy and safety, and to evaluate clinical cardiovascular outcomes.
Abstract

Keywords:
CETP inhibitorsFamilial hypercholesterolemiaHigh risk ASCVD patientsHyperlipidemiaLipid lowering therapy

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
7.2K